Sublingual Troche Medication Compounding: The Complete 2026 Patient and Provider Guide

Introduction: Why Sublingual Troche Medication Compounding Is Reshaping Personalized Medicine in 2026

Consider the patient who has tried three different hormone therapies and still battles fatigue, mood swings, and hot flashes. Or the individual who physically cannot swallow pills. Or the person whose body reacts to the dyes, fillers, and preservatives packed into mass-manufactured medications. For these patients, commercial pharmaceuticals often fall short. Increasingly, they are discovering a different solution: compounded sublingual troches.

A troche (pronounced “trō-key”) is a flavored, medicated lozenge placed under the tongue (sublingual) or between the cheek and gum (buccal). As it dissolves, the medication enters the bloodstream directly through the oral mucosa, bypassing the digestive system entirely.

In 2026, troches are gaining significant traction. Rising demand for personalized medicine, the maturing telehealth-to-compounding pipeline, and expanding therapeutic applications beyond hormone replacement therapy (including peptides, GLP-1 medications, and pain management) have pushed troches into the spotlight. With an estimated 30 to 40 million compounded prescriptions filled in the United States each year, this is not a niche corner of pharmacy. It is a substantial and growing field.

This guide covers what troches are, how they compare to every major delivery method, their honest limitations, the compounding process itself, and how to work with a qualified pharmacy. It is authored by Nationwide Compounding Rx®, a PCAB-accredited, USP 800-compliant pharmacy with 40 years of combined staff experience.

What Are Sublingual Troches? Anatomy, Mechanism, and How They Work

A troche is a small, flavored lozenge, often waxy or soft in texture, designed to dissolve slowly in the mouth over roughly 15 to 30 minutes. Unlike a hard candy meant to be sucked or a tablet meant to be swallowed, a troche is engineered to release its active ingredient gradually while resting against the oral tissue.

Patients place troches in one of two locations: sublingually (under the tongue) or buccally (between the cheek and gum). Both sites work well because the oral mucosa in these areas is non-keratinized, meaning it lacks the tough outer layer found on other surfaces. This makes it far more permeable to medication. According to a 2025 article in the Journal of Tissue Engineering, the oral mucosa offers an expansive absorption surface of approximately 170 cm².

The absorption pathway is straightforward: the medication dissolves, diffuses across the oral mucosa, enters the sublingual or buccal blood vessels, and reaches systemic circulation directly. Contrast this with a swallowed tablet, which travels to the stomach, into the small intestine, through the portal vein to the liver (where first-pass metabolism can dramatically reduce the drug’s potency), and only then into general circulation.

The word “troche” comes from the Greek trochiskos, meaning small wheel or disk. As a delivery method for drugs that are heavily metabolized by the liver, troche technology emerged in the late 1990s within 503A community pharmacies.

The Science of Sublingual Absorption: Bioavailability, First-Pass Bypass, and What the Research Actually Shows

First-pass hepatic metabolism refers to the liver’s rapid breakdown of a drug before it reaches the bloodstream. For certain drug classes, particularly hormones, this process can destroy a large fraction of an oral dose. Bypassing it means more of the medication actually does its job.

The absorption data illustrate the advantage. Sublingual and buccal troches achieve approximately 20% hormone absorption, compared to just 10 to 12% for gels and oil-based capsules. A 2025 bibliometric review published in PMC traced sublingual and buccal delivery research from the 1950s through 2025, identifying a major innovation phase between 2010 and 2025 that encompassed nanoparticles, mucoadhesive systems, and a wide range of therapeutic agents.

Clinical observation supports these findings. The Ruiz and Daniels observational cohort study (2014) found sublingual bioidentical hormone therapy superior to topical therapy for reducing menopausal symptoms, producing higher serum estradiol levels and greater progesterone absorption.

The pharmacokinetic advantages include shorter time-to-onset, reduced inter-patient variability, and more consistent delivery compared to oral tablets. A 2025 University of Debrecen review on oral cavity dosage forms provides further scientific grounding for these mucosal permeability differences.

Honest Limitations and Controversies: What Troche Advocates Do Not Always Disclose

A trustworthy guide addresses limitations openly. Troches are not appropriate for every patient or every situation.

Accidental swallowing is the most cited concern. If a patient swallows saliva containing dissolved medication before it is absorbed, that portion undergoes first-pass metabolism, partially negating the liver-bypass benefit.

There is also ongoing scientific debate over how much first-pass metabolism troches truly bypass. Critics point out that even sublingually absorbed hormones eventually circulate through the liver, so the liver-sparing benefit may be more modest than commonly claimed.

A specific concern for estrogen troches is estrone conversion. Sublingual estradiol can convert to estrone in the gut and liver if any portion is swallowed, and elevated estrone levels are associated with certain health concerns. Prescribers should weigh this carefully.

Taste remains a compliance barrier, especially for bitter active ingredients. Flavoring options such as peppermint, raspberry, and vanilla butternut help mitigate this.

Finally, compounded troches are not FDA-approved. They have not undergone FDA premarket review for safety, effectiveness, or quality. Dosing precision also depends heavily on correct administration. None of this makes troches inappropriate; it makes informed patient selection and prescriber guidance essential.

Head-to-Head: Sublingual Troches vs. Every Major HRT Delivery Method

The following comparison examines five criteria: absorption rate, onset speed, dosing convenience, customization flexibility, and key limitations. Individual patient response, hormone type, and prescriber judgment should always guide the final choice.

Troches vs. Transdermal Patches

Patches deliver hormones through the skin, bypassing first-pass metabolism much like troches. They provide steady-state delivery over 3 to 7 days, reducing dosing frequency. Troches offer faster onset and greater dose flexibility, while patches deliver more consistent plasma levels without any swallowing risk. However, patches may cause skin irritation or adhesion problems, and troches require twice-daily administration. Neither is universally superior.

Troches vs. Topical Creams and Gels

Creams and gels are applied to the skin and absorbed transdermally at roughly 10 to 12% for hormones, versus approximately 20% for troches. Topical products carry a real transfer risk to partners or children through skin contact. Troches may be preferred by patients seeking higher bioavailability without that transfer risk.

Troches vs. Hormone Pellets

Pellets are rice-sized implants inserted subcutaneously every 3 to 6 months, releasing hormones continuously. They offer the longest dosing interval and eliminate daily compliance concerns. The drawback is that pellets are irreversible once inserted; the dose cannot be adjusted until fully absorbed. Troches allow rapid dose adjustment at each refill based on lab results and carry no procedural or infection risk.

Troches vs. Intramuscular or Subcutaneous Injections

Injections achieve high bioavailability with rapid onset but often produce peak-and-trough fluctuations that some patients experience as mood or energy swings. Troches provide smaller, more frequent doses that may yield steadier levels for some patients, without needles. A 2026 ClinicalTrials.gov study comparing sublingual and oral estradiol coagulation effects illustrates the ongoing research into delivery-method differences.

Troches vs. Oral Capsules and Pills

Oral pills are subject to full first-pass metabolism. For hormones like progesterone and testosterone, this significantly reduces bioavailability. Oral micronized progesterone is a familiar example where much of the dose is metabolized before reaching circulation. Troches bypass this limitation and serve patients who cannot swallow pills as a non-invasive, needle-free alternative. Understanding how compounding differs from a regular pharmacy helps clarify why these customized formulations exist in the first place.

What Hormones and Medications Are Commonly Compounded as Troches?

Hormone Replacement Therapy leads the list: Estradiol, Estriol (often combined as “Biest”), Progesterone, Testosterone, DHEA, and Pregnenolone. Biest is a compounded blend of two estrogens (commonly 20% estradiol and 80% estriol, though ratios vary by prescriber) that cannot be replicated by any single FDA-approved product.

Other applications include:

• Pain Management: Ketamine troches for treatment-resistant depression and chronic pain, a growing application in 2026.
• Sexual Health: Sildenafil, tadalafil, or vardenafil combined with apomorphine.
• Weight Management: Semaglutide with B12 troches.
• Peptide Therapy: Sermorelin for growth hormone support.

Availability of specific compounds depends on the FDA’s 503A bulk drug substance list and the January 2025 policy change ending new interim category nominations.

Inside the Compounding Process: How Sublingual Troches Are Made

Understanding the process helps patients and prescribers evaluate pharmacy quality.

Step 1: Prescription Review and Active Ingredient Sourcing

The pharmacist reviews the prescription for clinical appropriateness, dose verification, and drug interactions. Active pharmaceutical ingredients (APIs) must come from FDA-inspected and cleared vendors and comply with USP/NF monograph standards or appear on the FDA’s approved bulk drug substances list. Nationwide Compounding Rx® purchases only the highest-grade chemicals from FDA-inspected vendors.

Step 2: Troche Base Selection

The troche base is the inactive carrier that holds the active ingredient and controls dissolution and texture. Common bases include water-soluble polyethylene glycol (PEG), silicone-based matrices for sustained release, and fatty acid bases for lipophilic drugs. Base selection affects absorption, palatability, and stability, and formulations can be prepared without allergens such as lactose, gluten, dyes, or preservatives.

Step 3: Compounding, Mold Filling, and Flavoring

The API is weighed and combined with the base using calibrated equipment, heated for homogeneity, then poured into molds producing lozenges of standardized weight (commonly 1 to 2 grams each). Flavoring agents such as peppermint, raspberry, or vanilla butternut are added at this stage. Molds cool under controlled conditions, and each batch is labeled with lot number, beyond-use date, active ingredients, strength, and patient-specific instructions.

Step 4: Quality Testing and Beyond-Use Dating

Quality testing may include potency verification, physical inspection, and sterility testing where applicable. Beyond-use dating (BUD) functions as the expiration date, assigned per USP Chapter 795 guidelines and stability data. PCAB-accredited pharmacies like Nationwide Compounding Rx® exceed minimum state requirements, and its USP 800-compliant facility eliminates cross-contamination risks that could affect dosing accuracy.

How to Use Sublingual Troches Correctly: Patient Administration Guide

1. Wash hands. Place the troche under the tongue or between the cheek and gum as directed.
2. Let it dissolve completely (about 15 to 30 minutes). Do not chew or swallow.
3. Minimize swallowing during dissolution to reduce first-pass metabolism.
4. Avoid eating, drinking, or rinsing for at least 15 minutes after full dissolution.
5. Rotate placement sites to prevent tissue irritation and optimize absorption.

For timing: hormone troches are typically dosed every 12 hours; testosterone troches for libido work best 2 hours before bedtime; progesterone troches are best taken at bedtime. Store as labeled, usually at room temperature away from heat and moisture, or refrigerated depending on the base. Patients should contact the pharmacy if troches are difficult to dissolve, unusually bitter, or cause unexpected symptoms.

The Regulatory Landscape for Compounded Troches in 2026: What Patients and Prescribers Must Know

503A vs. 503B: Understanding the Two Compounding Frameworks

503A pharmacies compound patient-specific prescriptions for identified individuals based on a valid prescription. 503B outsourcing facilities compound in bulk for providers under FDA registration and current good manufacturing practice (CGMP) standards. Nationwide Compounding Rx® operates as a 503A pharmacy, so every troche is made for a specific patient. Both types are barred from compounding copies of commercially available drugs, and compounded troches remain not FDA-approved. The FDA’s 503A guidance details these conditions.

The January 2025 FDA Policy Change and What It Means for Troche Compounding

Effective January 7, 2025, the FDA stopped placing newly nominated bulk drug substances into interim categories for 503A compounding. Pharmacies may not compound with newly proposed substances until the FDA completes its full review, which can take years. Some newer peptides previously available in interim status may no longer be legally compoundable. Prescribers should verify substances against the official FDA bulk drug substances page.

H.R. 5316: The Drug Shortage Compounding Patient Access Act (2025)

Introduced in the U.S. House in September 2025, H.R. 5316 would expand compounding access during drug shortages and clarify bulk substance monograph definitions. As of mid-2026, its status should be verified independently. The bill is significant because shortages (such as those affecting GLP-1 medications in 2024 and 2025) can make compounded alternatives a critical access point for patients.

PCAB Accreditation: Why It Matters More Than Most Patients Realize

PCAB (Pharmacy Compounding Accreditation Board) accreditation is the gold standard for compounding quality, and fewer than 1% of U.S. compounding pharmacies hold it. Accreditation involves rigorous on-site inspection, USP compliance verification, quality system assessment, staff training requirements, and ongoing surveillance.

The American Medical Association recommends that physicians use only PCAB-accredited compounding pharmacies. As ACHC and a 2026 Pharmacy Times analysis note, this accreditation serves as a vital safety net amid rising GLP-1 compounding demand. Nationwide Compounding Rx® has maintained PCAB accreditation since its early days of operation, placing it among a very small percentage of pharmacies nationwide. Patients and prescribers should always verify accreditation before establishing a relationship with a compounding pharmacy.

Emerging Applications: Beyond HRT

• Ketamine troches for treatment-resistant depression and chronic pain allow outpatient administration without IV infusion.
• Semaglutide with B12 troches for weight management, though semaglutide’s shortage status affects compounding legality; current FDA guidance should be verified before prescribing.
• Sermorelin troches for growth hormone support in anti-aging medicine and sports medicine.
• Erectile dysfunction combination troches addressing multiple mechanisms unavailable in any single FDA-approved product.
• Pediatric formulations flavored and dosed for children who cannot swallow pills.

All emerging applications are subject to the 503A bulk drug substance list and current FDA guidance.

For Prescribers: How to Write a Troche Prescription and Select a Compounding Partner

What to Include on a Compounded Troche Prescription

• Patient information: full name, date of birth, address.
• Prescriber information: name, NPI, DEA (if controlled), state license, contact.
• Drug information: active ingredient(s) and strength(s), dosage form, quantity, route.
• Compounding instructions: base preference, flavor, allergen exclusions.
• Directions: for example, “Place one troche under the tongue twice daily; allow to dissolve completely; do not swallow.”
• Refill authorization and clinical indication where required.

Prescribers are encouraged to contact the pharmacy before writing the prescription to discuss formulation options.

How to Evaluate a Compounding Pharmacy as a Clinical Partner

• Verify PCAB accreditation.
• Confirm USP 795 (non-sterile) and USP 800 (hazardous drug) compliance.
• Ask about FDA-inspected API sourcing.
• Inquire about potency and physical quality testing.
• Evaluate turnaround and shipping capabilities (Nationwide Compounding Rx® offers 1 to 2 business day turnaround and ships to 47 states plus Washington, D.C.).
• Assess pharmacist consultation availability and lab-based dose optimization.
• Confirm experience in the relevant therapeutic area.

Cost, Insurance, and Practical Access Considerations for Compounded Troches

Most compounded troches are not covered by commercial insurance because they are not FDA-approved. However, HSA and FSA funds are generally eligible for provider-prescribed compounded medications; patients should confirm eligibility with their plan administrator. Pricing depends on ingredient cost, compounding complexity, quantity, and overhead. Reputable pharmacies provide clear cost information upfront.

For many patients who have not found relief with commercial options, the degree of personalization justifies the out-of-pocket cost. The growing telehealth-to-compounding pipeline allows patients to consult a licensed provider online, receive a prescription, and have troches shipped directly. Nationwide Compounding Rx® ships to 47 states plus Washington, D.C. (excluding Alabama, California, North Carolina, and South Carolina).

Frequently Asked Questions About Sublingual Troche Medication Compounding

Are compounded troches safe? Troches from PCAB-accredited, USP-compliant pharmacies meet rigorous standards, though they are not FDA-approved. Safety depends heavily on pharmacy quality.

How long until hormone troches take effect? Sublingual delivery generally produces faster onset than oral or topical routes, but full hormone optimization typically takes weeks to months of consistent use.

Can troches be used by patients with allergies? Yes. Compounding can exclude allergens such as lactose, gluten, dyes, and preservatives.

What if a patient accidentally swallows a troche? Some of the dose undergoes first-pass metabolism, reducing effectiveness. Prescribers should be contacted if this occurs consistently.

How should troches be stored? Label instructions should be followed; typically room temperature away from heat and moisture, or refrigerated depending on the base. Troches should not be used past the beyond-use date.

Can children use troches? Yes. Pediatric compounding is a primary application, with child-friendly flavors and appropriate dosing.

Is a prescription required? Yes. All 503A compounded medications require a valid prescription.

How does a patient find a prescriber? Many integrative, functional medicine, and hormone specialist practices prescribe compounded medications, and telemedicine platforms are expanding access significantly.

Conclusion: Sublingual Troches as a Precision Medicine Tool

Sublingual troches offer direct absorption through the oral mucosa, first-pass metabolism bypass, customizable dosing and formulation, and broad applicability across HRT, pain management, sexual health, weight management, and peptide therapy. They are a powerful tool, but not without limitations. Accidental swallowing, the ongoing debate over liver-sparing benefits, and the non-FDA-approved status are all real considerations that informed patients and prescribers must weigh carefully.

The quality of the compounding pharmacy matters as much as the delivery method itself. PCAB accreditation, USP compliance, and FDA-inspected API sourcing are non-negotiable quality markers. With a shifting regulatory landscape shaped by the January 2025 FDA policy change and pending legislation such as H.R. 5316, staying informed is essential. Personalized medicine means no patient has to settle for a one-size-fits-all solution.

Partner With Nationwide Compounding Rx® for Expert Sublingual Troche Compounding

Patients and providers ready to explore whether compounded sublingual troches are the right fit can turn to Nationwide Compounding Rx®: PCAB-accredited, USP 800-compliant, and backed by 40 years of combined staff experience, with 1 to 2 business day turnaround, shipping to 47 states plus Washington, D.C., and APIs sourced exclusively from FDA-inspected vendors.

For patients: Ask a provider about a compounded troche prescription, then contact Nationwide Compounding Rx® to discuss formulation options.

For prescribers: Contact the pharmacist team to discuss patient needs and explore a compounding partnership or establish a prescriber account.

Contact Information:

• Phone: 480-499-8379
• Toll-Free: 1-833-650-9836
• Fax: 480-699-5341
• Website: www.NationwideCompounding.com
• Address: 14000 N. Hayden Rd., Suite 104, Scottsdale, AZ 85260
• Hours: Monday through Friday, 7:00 a.m. to 3:30 p.m.

Nationwide Compounding Rx® proudly serves patients and providers in 47 states plus Washington, D.C. Contact the pharmacy directly to confirm service availability in your state.